Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Asset Writedowns and Impairment (2023 - 2024)

Taysha Gene Therapies (TSHA) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with $4.8 million as the latest value for Q3 2024.

  • Quarterly Asset Writedowns and Impairment rose 685.39% to $4.8 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $4.8 million through Dec 2025, down 18.04% year-over-year, with the annual reading at $4.8 million for FY2024, 354.27% up from the prior year.
  • Asset Writedowns and Impairment hit $4.8 million in Q3 2024 for Taysha Gene Therapies, up from $449000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $4.8 million in Q3 2024 to a low of $449000.0 in Q4 2023.